RI MASAKI 李政樹

Researcher Number	00567539
Other IDs
Affiliation (Current)	2025: 名古屋市立大学, 医薬学総合研究院(医学), 准教授
Affiliation (based on the past Project Information) *help	2022 – 2025: 名古屋市立大学, 医薬学総合研究院(医学), 准教授 2019 – 2021: 名古屋市立大学, 医薬学総合研究院(医学), 講師 2017 – 2018: 名古屋市立大学, 大学院医学研究科, 講師 2016: 名古屋市立大学, 大学院医学研究科, 助教 2011 – 2016: 名古屋市立大学, 医学(系)研究科(研究院), 助教 2014: 名古屋市立大学, 大学院医学研究科, 助教
Review Section/Research Field	Principal Investigator Basic Section 50020:Tumor diagnostics and therapeutics-related / Tumor therapeutics / Hematology Except Principal Investigator Basic Section 54010:Hematology and medical oncology-related / Tumor therapeutics / Hematology
Keywords	Principal Investigator 多発性骨髄腫 / cfDNA / 感受性 / 耐性 / 免疫回避 / 血小板 / エキソソーム / 代謝物 / 血漿 / バイオマーカー … More / 感受性因子 / オミックス解析 / 末梢血 / レナリドミド / lipidomics / lenalidomide / Multiple myeloma / 薬剤耐性 / 分子標的治療 / 耐性機序 / RNAシークエンス / カルフィルゾミブ / ボルテゾミブ / 薬剤耐性機序 / プロテアソーム阻害剤 / T細胞性リンパ腫 / XBP1 / 骨髄腫 … More Except Principal Investigator 多発性骨髄腫 / バイオマーカー / 感染症 / 免疫病態 / 二重特異性抗体 / ゲノムバイオマーカー / cfDNA / 薬剤感受性 / クローン進化 / cell free DNA / リキッドバイオプシー / ボルテゾミブ / リピドミクス / LC－MS / 血小板 / Bortezomib / 薬剤反応性 / 癌 / HDAC阻害剤 / 骨髄腫 / リンパ腫 / 薬剤耐性 / がん / 医療 Less

多発性骨髄腫のCAR-T細胞療法抵抗性機序の解明を目的とした血漿成分の網羅的解析研究Principal Investigator
- Principal Investigator
  
  李政樹
- Project Period (FY)
  2025 – 2027
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Nagoya City University
Biomarker analysis predicting efficacy and immune dysfunction in myeloma patients receiving bispecific antibodies
- Principal Investigator
  
  飯田真介
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 54010:Hematology and medical oncology-related
- Research Institution
  Nagoya City University
多発性骨髄腫における抗腫瘍免疫回避の機序解明を目的とした血漿の網羅的解析Principal Investigator
- Principal Investigator
  
  李政樹
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Nagoya City University
Exploratory study to find predictive genomic biomarkers using liquid biopsy in multiple myeloma
- Principal Investigator
  
  Iida Shinsuke
- Project Period (FY)
  2020 – 2023
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 54010:Hematology and medical oncology-related
- Research Institution
  Nagoya City University
Exploration of factors related to sentsitivity of lenalidomide therapy by omics analysisPrincipal Investigator
- Principal Investigator
  
  Masaki Ri
- Project Period (FY)
  2019 – 2023
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Nagoya City University
Elucidation of the mechanism of resistance to proteasome inhibitors and search for novel molecular targets to overcome resistancePrincipal Investigator
- Principal Investigator
  
  RI MASAKI
- Project Period (FY)
  2016 – 2019
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Tumor therapeutics
- Research Institution
  Nagoya City University
血中の抗炎症性脂質により腫瘍が分子標的薬に高感受性を示す作用機序
- Principal Investigator
  
  桶本和男
- Project Period (FY)
  2015 – 2016
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Tumor therapeutics
- Research Institution
  Nagoya City University
Mechanisms of resistance against histone deacetylase inhibitors in refractory lymphoid malignancies
- Principal Investigator
  
  IIDA SHINSUKE
- Project Period (FY)
  2012 – 2014
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Hematology
- Research Institution
  Nagoya City University
Study of the agent targetting for ER stress-induced XBP1 activity in refractory lymphoid malignancies.Principal Investigator
- Principal Investigator
  
  RI MASAKI
- Project Period (FY)
  2011 – 2013
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Hematology
- Research Institution
  Nagoya City University

All 2021 2020 2016 2013 2012 Other

All Journal Article Presentation Book

[Book] 造血器腫瘍とエピジェネティクス-治療への応用と新たな展開-2012
- Author(s)
  李政樹、飯田真介
- Publisher
  医薬ジャーナル社
- Data Source
  KAKENHI-PROJECT-24591406
[Journal Article] HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1)2021
- Author(s)
  Ri Masaki、Iida Shinsuke、Maruyama Dai、Sakabe Aya、Kamei Ryo、Nakashima Takuto、Tohkin Masahiro、Osaga Satoshi、Tobinai Kensei、Fukuhara Noriko、Miyazaki Kana、Tsukamoto Norifumi、Tsujimura Hideki、Yoshimitsu Makoto、Miyamoto Kenichi、Tsukasaki Kunihiro、Nagai Hirokazu
- Journal Title
  
  Cancer Science
  
  Volume: 112 Issue: 12 Pages: 5011-5019
- DOI
  10.1111/cas.15158
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08759
[Journal Article] Clinical utility of target capture‐based panel sequencing in hematological malignancies: A multicenter feasibility study2020
- Author(s)
  Yasuda T, Sanada M, Nishijima D, Kanamori T, Iijima Y, Hattori H, Saito A, Miyoshi H, Ishikawa Y, Asou N, Usuki K, Hirabayashi S, Kato M, Abe M.
- Journal Title
  
  Cancer Science
  
  Volume: 111 Issue: 9 Pages: 3367-3378
- DOI
  10.1111/cas.14552
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K08329, KAKENHI-PROJECT-19K08861, KAKENHI-PROJECT-20K08723, KAKENHI-PROJECT-20K08759, KAKENHI-PROJECT-19H05656
[Journal Article] Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort.2020
- Author(s)
  Kanamori T, Sanada M, Ri M, Ueno H, Nishijima D, Yasuda T, Tachita T, Narita T, Kusumoto S, Inagaki A, Ishihara R, Murakami Y, Kobayashi N, Shiozawa Y, Yoshida K, Nakagawa MM, Nannya Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Horibe K, Handa H, Ogawa S, Iida S.
- Journal Title
  
  Br J Haematol.
  
  Volume: - Issue: 5 Pages: 755-763
- DOI
  10.1111/bjh.16720
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K10136, KAKENHI-PROJECT-18K16103, KAKENHI-PROJECT-20K08723, KAKENHI-PROJECT-20K08759, KAKENHI-PROJECT-19H05656
[Journal Article] Expression, mutation, and methylation of CRBN-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.2020
- Author(s)
  Tachita T, Kinoshita S, Ri M, Aoki S, Asano A, Kanamori T, Yoshida T, Totani H, Ito A, Kusumoto S, Komatsu H, Yamagata K, Kubo K, Tohkin M, Fukuda S, Iida S.
- Journal Title
  
  Cancer Science
  
  Volume: 111 Issue: 4 Pages: 1333-1343
- DOI
  10.1111/cas.14352
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08759
[Journal Article] Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing2012
- Author(s)
  Ri M, Iida S, et al. (他16名)
- Journal Title
  
  Blood Cancer J
  
  Volume: 2;7
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23791085
[Presentation] Cytogenetic risk/Genome-based medicine in multiple myeloma2021
- Author(s)
  Takashi Kanamori, Shinsuke Iida
- Organizer
  The 12th. JSH International Symposium 2021 in Kamakura
- Data Source
  KAKENHI-PROJECT-20K08759
[Presentation] Serum lipid metabolomics can predict sensitivity to bortezomib treatment in multiple myeloma2016
- Author(s)
  李　政樹
- Organizer
  第78回日本血液学会学術集会
- Place of Presentation
  パシフィコ横浜　会議センター　3F
- Year and Date
  2016-10-13
- Data Source
  KAKENHI-PROJECT-15K06877
[Presentation] How to overcome acquired resistance against novel agents in multiple myeloma; Strategies based on the responsible mechanism for bortezomib resistance2013
- Author(s)
  Masaki Ri, Shinsuke Iida
- Organizer
  第10回日本臨床腫瘍学会学術集会
- Place of Presentation
  大阪
- Year and Date
  2013-07-26
- Data Source
  KAKENHI-PROJECT-23791085
[Presentation] Reduced expression of HDAC3 contributes to the resistance against HDAC inhibitor, vorinostat (SAHA) in mature lymphoid malignancies.
- Author(s)
  Ding J, Ri, M, Narita T, Masaki A, Mori F, Ito A, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Niimi A, Iida S
- Organizer
  54th. Annual Meeting of American Society of Hematology
- Place of Presentation
  Georgia World Congress Center (Atlanta, USA)
- Data Source
  KAKENHI-PROJECT-24591406

1. IIDA SHINSUKE (50295614)

# of Collaborated Projects: 3 results

# of Collaborated Products: 5 results
2. 前川京子 (70270626)

# of Collaborated Projects: 3 results

# of Collaborated Products: 0 results
3. 桶本和男 (50415486)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
4. 三田貴臣 (00792475)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
5. SANADA Masashi

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
6. 安部正博

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

RI MASAKI 李 政樹

Research Projects

Research Products

Co-Researchers

多発性骨髄腫のCAR-T細胞療法抵抗性機序の解明を目的とした血漿成分の網羅的解析研究Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Biomarker analysis predicting efficacy and immune dysfunction in myeloma patients receiving bispecific antibodies

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

多発性骨髄腫における抗腫瘍免疫回避の機序解明を目的とした血漿の網羅的解析Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Exploratory study to find predictive genomic biomarkers using liquid biopsy in multiple myeloma

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Exploration of factors related to sentsitivity of lenalidomide therapy by omics analysisPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Elucidation of the mechanism of resistance to proteasome inhibitors and search for novel molecular targets to overcome resistancePrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

血中の抗炎症性脂質により腫瘍が分子標的薬に高感受性を示す作用機序

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Mechanisms of resistance against histone deacetylase inhibitors in refractory lymphoid malignancies

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Study of the agent targetting for ER stress-induced XBP1 activity in refractory lymphoid malignancies.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Book] 造血器腫瘍とエピジェネティクス-治療への応用と新たな展開-2012

Author(s)

Publisher

Data Source

[Journal Article] HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1)2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Clinical utility of target capture‐based panel sequencing in hematological malignancies: A multicenter feasibility study2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort.2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Expression, mutation, and methylation of CRBN-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.2020

Author(s)

Journal Title

RI MASAKI 李政樹